Genmab annouces positive top-line results for Arzerra

27-Aug-2009 - Denmark

Genmab A/S announced positive top-line results from the Phase II study of Arzerra™ (ofatumumab) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with previously untreated follicular non-Hodgkin’s lymphoma (NHL).

A total of 58 patients were treated in the study. The overall response rate (ORR) in patients treated with 500 mg of ofatumumab (n=29) was 90%, including 24% complete remissions (CR), and 45% complete remissions/unconfirmed (CRu). In patients treated with 1000 mg of ofatumumab (n=29), the ORR was 100% including 38% CR, and 17% CRu.

There were no unexpected safety findings reported during treatment and within 30 days after last infusion. The most common adverse events of grade 3 or 4 (greater than 10 percent) were leucopenia and neutropenia. No events of sepsis or pneumonia were observed, and no deaths reported in the trial.

Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

Ofatumumab is an investigational, fully human monoclonal antibody that binds specifically to the small and large extracellular loops of the CD20 molecule proximal to the cell membrane. The CD20 molecule is a key target in B-cell malignancy therapy because it is expressed on most B-cells. Ofatumumab is not yet approved in any country.

Other news from the department research and development

Most read news

More news from our other portals

Last viewed contents

MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program - First HuCAL-based Antibody to Enter Clinical Trial in Second Indication

Viruses on the run - ETH Zurich Professor Ari Helenius awarded Benoist Prize

Viruses on the run - ETH Zurich Professor Ari Helenius awarded Benoist Prize

New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future

New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe

Evotec Receives a Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim

UF study strengthens concerns about long-term use of certain painkillers

Scientists at Almac and Queen’s University Belfast discover novel approach to treat cancer patients.

Restoring chemotherapy sensitivity by boosting microRNA levels

Restoring chemotherapy sensitivity by boosting microRNA levels

Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer

Centocor, Inc. - Horsham, USA

Centocor, Inc. - Horsham, USA

Advanced Cell Technology Announces Creation of Human Embryonic Stem Cell Lines Without the Destruction of Embryos - Breakthrough Approach Improves Efficiency to Levels Reported in the Conventional Stem Cell Derivation Techniques